GlobeNewsWire
16 Jun 2026, 12:45 UTC · 13w ago
Verdict
Headline takes no side. We score PPCB +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Propanc Biopharma plans to submit a Phase 1b, First-In-Human (FIH) clinical trial application in Australia in 2026.
More positive than 92% of claims this week
The company has engaged a European CDMO to manage the pre-production, engineering run, and GMP manufacture of its lead asset, PRP.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 65% of claims this week
The Phase 1b study will target 30–40 advanced cancer patients with solid tumors using a novel combination of trypsinogen and chymotrypsinogen.
More positive than 55% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company is making tangible progress toward its Phase 1b clinical trial by securing a CDMO partner and planning GMP production for its lead asset.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Benzinga
12h ago
—
No price for PPCB right now — the quote feed didn't answer.
PPCB chart →
